14.7  0 (0%)		01-16 16:00
Open: 14.71 High: 14.71 Volume: 2,376,385		Pre. Close: 14.7 Low: 14.7 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Amryt Pharma plc is a commercial-stage biopharmaceutical company committed to enhancing the lives of individuals with rare and orphan diseases. The firm achieves this by acquiring, developing, and bringing to market specialized therapies. Among its current offerings, Amryt provides: Metreleptin, prescribed as a dietary adjunct and replacement therapy, addresses complications arising from leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Oral octreotide serves as a long-term maintenance solution for those with acromegaly. Lomitapide, used in conjunction with a low-fat diet and other lipid-lowering medications, aids adults diagnosed with Homozygous familial Hypercholesteraemia. Its pipeline features promising investigational therapies, including Oleogel-S10, which targets the skin manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB)—a severe and uncommon genetic skin disorder impacting both children and adults. Additionally, AP103 is a pre-clinical gene therapy under development for dystrophic EB. Amryt's products are distributed across the Americas, Europe, and the Middle East. Established in 2015, Amryt Pharma plc maintains its headquarters in Dublin, Ireland.

Wed, 22 Mar 2023
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici - Yahoo Finance

Mon, 09 Jan 2023
Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B - Yahoo Finance

Sun, 08 Jan 2023
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - GlobeNewswire

Thu, 03 Nov 2022
Amryt Reports Q3 2022 Financial and Operational Results - GlobeNewswire

Thu, 05 Aug 2021
Amryt Successfully Completes Acquisition of Chiasma, Inc., - GlobeNewswire

Wed, 05 May 2021
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date